GLP1R and metabolic dysfunction-associated steatohepatitis: pioglitazone and GLP-1 receptor agonists have been shown to improve histological features of NASH (i.e., steatosis, ballooning, lobular inflammation) or achieve resolution of NASH without further deterioration of fibrosis and therefore are widely used in patients with NAFLD and coexistent T2DM36.